Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Inflammation in multiple sclerosis: the good, the bad, and the complex.

Gianvito Martino1, Luciano Adorini, Peter Rieckmann

  • 1Department of Neuroscience, San Raffaele Scientific Institute, Milan, Italy. g.martino@hsr.it

The Lancet. Neurology
|July 10, 2003
PubMed
Summary

Inflammation in multiple sclerosis (MS) may be beneficial, challenging traditional views. Targeted anti-inflammatory treatments are crucial, as broad application may not be appropriate for all MS patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

REBISTART: Adherence of Patients with Multiple Sclerosis to Treatment with Subcutaneous Interferon Beta in the Context of a Patient Support Program.

Neurology and therapy·2024
Same author

Long-term management of multiple sclerosis patients treated with cladribine tablets beyond year 4.

Expert opinion on pharmacotherapy·2022
Same author

Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper).

Therapeutic advances in neurological disorders·2021
Same author

[Multiple sclerosis treatment consensus group (MSTCG): position paper on disease-modifying treatment of multiple sclerosis 2021 (white paper)].

Der Nervenarzt·2021
Same author

Long-term management of multiple sclerosis patients treated with cladribine tablets: an expert opinion.

Expert opinion on pharmacotherapy·2020
Same author

Alemtuzumab as rescue therapy in a cohort of 50 relapsing-remitting MS patients with breakthrough disease on fingolimod: a multi-center observational study.

Journal of neurology·2018

Area of Science:

  • Neuroimmunology
  • Pathophysiology of Multiple Sclerosis (MS)

Background:

  • Traditionally, inflammation is considered detrimental in multiple sclerosis (MS) pathogenesis.
  • Emerging evidence from genetic, imaging, and immunopathological studies questions this view.
  • The role of inflammation in MS is complex and requires nuanced understanding.

Purpose of the Study:

  • To challenge the simplistic view of inflammation as solely detrimental in MS.
  • To explore the potentially beneficial role of tightly regulated inflammation in MS.
  • To re-evaluate the appropriateness of broad anti-inflammatory treatments in MS.

Main Methods:

  • Review of genetic data.
  • Analysis of magnetic-resonance-imaging (MRI) studies.
  • Examination of immunopathological evidence.

Related Experiment Videos

Main Results:

  • Inflammation in MS appears to be tightly regulated.
  • The net effect of inflammation may be beneficial in certain contexts of MS.
  • This complexity explains variable responses to anti-inflammatory agents in MS trials.

Conclusions:

  • The simplistic view of inflammation as detrimental in MS is challenged.
  • Beneficial roles of regulated inflammation in MS pathophysiology exist.
  • Precise targeting of inflammatory pathways and timing of interventions are critical for effective MS treatment.